Dexcom reported strong 2025 revenues of $4.66bn, driven by demand for its continuous glucose monitoring systems, with Q4 2025 earnings at $1.26bn. Despite this, the company’s 2026 revenue forecast of $5.16bn to $5.25bn, while showing double-digit growth, fell slightly below analysts’ expectations. CEO Jake Leach outlined plans for 2026, including increasing awareness of the new G7 15-day device, enhancing customer experience, and expanding international market share, particularly with the Smart Basal launch.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Dexcom reports 2025 revenues of $4.66bn yet 2026 outlook lags analyst expectations
Dexcom reported strong 2025 revenues of $4.66bn, driven by demand for its continuous glucose monitoring systems, with Q4 2025 earnings at $1.26bn. Despite this, the company’s 2026 revenue forecast of $5.16bn to $5.25bn, while showing double-digit growth, fell slightly below analysts’ expectations. CEO Jake Leach outlined plans for 2026, including increasing awareness of the new G7 15-day device, enhancing customer experience, and expanding international market share, particularly with the Smart Basal launch.